Skip to main content

Table 2 The clinical characteristics of 20 cases diagnosed with de novo or R/R AML

From: Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells

Patient No

Age (yrs)

Gender

WBC (× 109)

LDH (U/L)

Blasts (%)

Karyotype

Molecular features

1

68

F

4.85

Normal

24

Normal

/

2

66

M

48.34

High

36

46, XY, t (2;22)

TET2

3

55

F

21.38

High

69

Complex

NPM1, TET2, ASXL1

4

57

M

47.34

High

74

46, XY, t (8;21)

AML-ETO

5

32

M

324.4

High

92

46, XX, inv (16)

CBFB-MYH11

6

60

M

52.12

Normal

43

Normal

CEBPA, TET2

7

64

F

16.12

High

62

Normal

IDH, Runx1

8

28

F

15.63

High

52

46, XY, inv (16)

CBFB-MYH11, ASXL1, CEBPA

9

44

M

23.56

Normal

46

Normal

/

10

9

F

581.8

High

92

ND

/

11

11

M

48.65

High

57

Normal

/

12

6

F

231.2

High

78

Complex

FLT3-ITD

13

5

M

180.3

High

43

46, XX, del (14) (q32)

/

14

10

F

53.1

High

64

Normal

c-KIT

15

58

M

45.3

Normal

36

45, XY, − 7

TP53

16

46

F

153.2

High

76

Complex

FLT3-ITD

17

32

F

201.2

High

91

46, XX

ASXL1

18

40

M

53.4

High

45

45, XY, − 5

/

19

19

M

75.3

High

58

46, XY

DNMT3A

20

23

F

121.5

Normal

48

Normal

CEBPA